Candel Therapeutics Inc
CADL6.310USD
+0.020+0.32%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
310.75MMarket Cap
LossP/E TTM
More Details of Candel Therapeutics Inc Company
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Company Info
Ticker SymbolCADL
Company nameCandel Therapeutics Inc
IPO dateJul 27, 2021
CEODr. Paul Peter Tak, M.D., Ph.D.
Number of employees38
Security typeOrdinary Share
Fiscal year-endJul 27
Address117 Kendrick Street,
CityNEEDHAM
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02494
Phone16179165445
Websitehttps://www.candeltx.com/
Ticker SymbolCADL
IPO dateJul 27, 2021
CEODr. Paul Peter Tak, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Edward J. Benz, Jr., M.D.
Dr. Edward J. Benz, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Seshu Tyagarajan, Ph.D.
Ms. Seshu Tyagarajan, Ph.D.
Chief Technical and Development Officer
Chief Technical and Development Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. W. Garrett Nichols, M.D.
Dr. W. Garrett Nichols, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Revenue Breakdown
FY2024
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 24
Updated: Sat, May 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.50%
Manning (Paul B.)
5.38%
Acorn Capital Advisors, LLC
4.92%
Baker Bros. Advisors LP
4.64%
Aguilar-Cordova (Estuardo)
4.61%
Other
66.94%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.50%
Manning (Paul B.)
5.38%
Acorn Capital Advisors, LLC
4.92%
Baker Bros. Advisors LP
4.64%
Aguilar-Cordova (Estuardo)
4.61%
Other
66.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.01%
Individual Investor
16.48%
Investment Advisor/Hedge Fund
6.21%
Hedge Fund
5.99%
Corporation
2.48%
Research Firm
0.64%
Bank and Trust
0.09%
Pension Fund
0.02%
Insurance Company
0.02%
Other
39.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
162
31.98M
60.95%
-104.17K
2025Q1
160
30.10M
67.51%
-1.81M
2024Q4
131
27.38M
62.24%
+9.09M
2024Q3
115
17.10M
48.26%
-703.44K
2024Q2
98
16.89M
49.23%
+872.97K
2024Q1
67
14.85M
50.59%
-1.40M
2023Q4
65
14.94M
51.56%
-1.48M
2023Q3
68
15.61M
53.96%
-846.00K
2023Q2
65
15.70M
54.30%
-590.47K
2023Q1
64
16.17M
55.93%
-250.07K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
7.09M
13.5%
+766.60K
+12.13%
Mar 31, 2025
Manning (Paul B.)
2.82M
5.38%
+500.00K
+21.52%
Apr 21, 2025
Acorn Capital Advisors, LLC
2.58M
4.92%
+428.26K
+19.90%
Jun 25, 2025
Baker Bros. Advisors LP
2.44M
4.64%
-544.79K
-18.27%
Mar 31, 2025
Aguilar-Cordova (Estuardo)
2.42M
4.61%
+190.92K
+8.57%
Apr 21, 2025
Aguilar (Laura K)
2.36M
4.49%
-690.05K
-22.65%
Apr 21, 2025
The Vanguard Group, Inc.
1.74M
3.31%
+396.95K
+29.64%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.61M
3.06%
+515.63K
+47.27%
Mar 31, 2025
BKB Growth Investments LLC
1.30M
2.48%
+750.00K
+135.44%
Apr 21, 2025
Portolan Capital Management, L.L.C.
881.18K
1.68%
+127.44K
+16.91%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ALPS Medical Breakthroughs ETF
0.17%
Vanguard US Momentum Factor ETF
0.08%
iShares Micro-Cap ETF
0.05%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0%
View more
ALPS Medical Breakthroughs ETF
Proportion0.17%
Vanguard US Momentum Factor ETF
Proportion0.08%
iShares Micro-Cap ETF
Proportion0.05%
iShares Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
